The best person for your next role might not live near your office—or even in the same country.

More companies are realizing they don't need to open entities everywhere just to access global talent. Instead, they're using EOR to hire internationally faster, stay compliant, and avoid building local infrastructure before they're ready.

Oyster's EOR helps companies hire, pay, and support employees in 180+ countries while Oyster handles payroll, compliance, taxes, and local employment requirements.

See how it works

👋 Hi, it’s Rohit Malhotra and welcome to the FREE edition of Partner Growth Newsletter, my weekly newsletter doing deep dives into the fastest-growing startups and S1 briefs. Subscribe to join readers who get Partner Growth delivered to their inbox every Wednesday morning.

If you’re new, not yet a subscriber, or just plain missed it, here are some of our recent editions.

_{Interested in sponsoring these emails? See our partnership options here.}

Subscribe to the Life Self Mastery podcast, which guides you on getting funding and allowing your business to grow rocketship. 

Previous guests include Guy Kawasaki, Brad Feld, James Clear, Nick Huber, Shu Nyatta and 350+ incredible guests.

Dassault Systèmes' acquisition of ArisGlobal is not a simulation software maker wandering into pharma compliance because the category looked defensive. It is Pascal Daloz who added the Chairman's seat to the CEO job in February — closing a loop Dassault has been building since it paid $5.8 billion for Medidata in 2019.

On the surface: a French 3D and simulation company pays $1.8 billion in cash, plus up to $200 million tied to AI revenue milestones, for a compliance vendor expected to do $175 million in revenue this year. Better than ten times revenue, before the earnout, for a business most operators outside life sciences have never heard of. The kind of deal that gets a line in the trade press and a raised eyebrow at the multiple.

But Dassault already owned the front of the drug lifecycle: discovery through BIOVIA, clinical trials and real-world data through Medidata, manufacturing through DELMIA. What it never owned was the regulated back end safety reporting, pharmacovigilance, regulatory submissions, the layer where a therapy lives for the decades after approval. ArisGlobal is that layer. It processes more than 12 million patient safety reports a year across half of the top 50 global biopharma companies. That is not a compliance purchase. It is the feedback signal that the real-world evidence loop that gives a simulation engine something to learn from once the molecule leaves the lab.

In 1987, Deepak Abbhi built one of the industry's first systems for automating adverse-event reports - the filings drugmakers owe regulators every time a patient reacts badly to a therapy. That company became ArisGlobal. Thirty-nine years later, Dassault Systèmes is paying up to $2 billion for it: $1.8 billion in cash, plus $200 million tied to AI revenue. The reason isn't the software. It is the four decades ArisGlobal spent becoming the safety-reporting backbone for half the top 50 drugmakers.

The asset was built for this. Nordic Capital bought ArisGlobal in 2019, moved it off legacy architecture to SaaS, added two acquisitions, and built NavaX, the AI engine that automates safety-case work customers used to do by hand. It now processes over 12 million safety reports a year on roughly $175 million of revenue.

That is the asset Dassault needs. It already owns the front of the lifecycle — it paid $5.8 billion for Medidata in 2019 for clinical trials and real-world data. What it never owned was the regulated back end. You cannot build a four-decade compliance install base while the market reprices around AI. So it bought the incumbent

Dassault agreed to pay up to $2 billion for ArisGlobal: $1.8 billion in cash at closing, plus $200 million tied to multi-year AI revenue milestones. On $175 million of 2026 revenue, that is more than 10x revenue - the multiple you pay for an AI-native, embedded compliance platform coming out of a private-equity full exit, not the multiple for legacy pharma software. Close is expected in second-half 2026, subject to regulatory approval

The number that matters is the $200 million. It is contingent, tied to AI revenue, which tells you what Dassault is underwriting: NavaX, not the install base. The $1.8 billion base is roughly a third of what Dassault paid for Medidata in 2019, buying the one layer that deal left uncovered.

Dassault is funding it entirely with cash on hand and expects it to lift both revenue growth and EPS in Year 1 when deals this size usually dilute. What Dassault is buying is not a standalone business to run. It is a data layer to wire into the platform. ArisGlobal's safety and regulatory engine becomes part of NavaX and XDI, the continuous evidence loop the stack was missing.

Three numbers do the explaining here.

One. Dassault paid $1.8 billion for $175 million of 2026 revenue - about 10x, and 11x once the $200 million earnout counts. Set that against Medidata: $5.8 billion in 2019 for a business doing $636 million, roughly 9x. Dassault is paying more per revenue dollar for the far smaller company. It is not buying scale - 1,300 people, $175 million in sales. It is buying position: the safety and regulatory system embedded in half the top 50 drugmakers, clearing 12 million reports a year.

Two. That position compounds. NavaX delivers more than 30% productivity gains, in a compliance market growing double-digits toward $7.5 billion by 2030 — where ArisGlobal sits at roughly 2% today. The $200 million earnout, tied entirely to AI revenue, is Dassault betting that share widens.

Three. Dassault is funding the whole thing with cash on hand, keeps its balance-sheet flexibility, and expects the deal to lift both revenue growth and EPS in Year 1 - where most acquisitions this size dilute before they add. The premium isn't for the revenue. It is for the loop it closes.

$1.8 billion in cash. Up to $200 million more - but only if the AI revenue shows up. That second number is the whole structure.

Most buyers pay one price for the company and hope the AI story is real. Dassault split the check. It's paying full value now for what ArisGlobal already is and paying for NavaX only if NavaX actually delivers. That's not a premium. It's a hedge.

And this isn't an acquisition to run. It's an absorption. Kroger bought Giant Eagle and kept the name, the HQ, the leadership, the loyalty program. Dassault is doing the opposite ie. ArisGlobal's safety and regulatory engine gets wired straight into NavaX and XDI. The platform dissolves into the platform.

Funded entirely from cash. No debt. No dilution. Accretive to revenue growth and EPS in Year 1 where deals this size usually cost two years before they pay. The precedent is Medidata. Bought in 2019, folded in as a brand, not a subsidiary

ArisGlobal does $175 million in revenue.

Dassault is paying $1.8 billion for it. Here's the operator lesson buried in that number:

You don't get acquired for what you're worth. You get acquired for what the buyer can't replicate.

ArisGlobal isn't big. 1,300 people. But it clears 12 million safety reports a year for half the top 50 drugmakers, inside regulated workflows nobody rips out casually. Four decades of that. You can't rebuild it on a roadmap. So the moat was never the software. It was the position.

And notice what made it worth 10x revenue: Dassault already owned the front of the drug lifecycle. ArisGlobal completed a loop. The second piece is worth more than the first — because it's the one that makes everything already on the balance sheet finally pay off.

That's the playbook, whether you're building to sell or building to last:

Don't compete on scale. Get embedded somewhere the giant can't build fast enough to catch you. Then let the loop do the pricing.

Dassault is wagering on four things being true at once.

One. AI is where compliance spend goes now, not more software. The market grows double-digit toward $7.5 billion by 2030, and NavaX already delivers 30%+ productivity gains. Dassault is betting the value sits in the AI engine which is why $200 million of the price rides on AI revenue, not seats.

Two. Buying the incumbent beats building the back end. Dassault has owned the front of the lifecycle since paying $5.8 billion for Medidata in 2019 but never built the regulated safety layer itself. It is betting a platform embedded in half the top 50 drugmakers wins faster than coding pharmacovigilance from scratch.

Three. Absorption beats autonomy. ArisGlobal doesn't stay standalone; its engine folds into NavaX and XDI, the way Medidata became a brand, not a subsidiary. Dassault is betting the value is in wiring the data into the platform, not running a business.

Four. The loop is worth more than the parts. Its thesis is the virtual twin ie simulation across discovery, trials and manufacturing. It is betting real-world safety outcomes fed back into that engine build a loop no compliance vendor or simulation company can match alone.

Veeva is the obvious loser.

The biggest name in life sciences software just watched a rival match its compliance suite and pair it with something Veeva doesn't have: simulation across the entire drug lifecycle. Veeva owns the cloud. Dassault now owns the loop. But Veeva isn't the real loser.

Oracle is. Its Argus database has run drug safety for two decades — legacy, on-prem, the exact workflow NavaX was built to replace. ArisGlobal was already taking that share. Now it takes it with Dassault's balance sheet behind it.

Still not the real loser.

The real loser is the independent vendor.

Every best-of-breed safety, regulatory, or quality tool selling one slice of the workflow just became a feature. When the buyer wants molecule-to-outcome on one platform, a point solution isn't a competitor. It's a gap to fill.

That's how consolidation works. It doesn't beat the small players. It makes them irrelevant.

And the quiet loser? The customer. Half the top 50 drugmakers now run mission-critical compliance on a roadmap they no longer control.

Three threads worth pulling.

One. PE just proved a repeatable exit playbook for regulated software. Nordic Capital bought ArisGlobal in 2019, spent seven years turning a legacy pharma vendor cloud-native and AI-enabled, and sold to a strategic at more than 10x revenue. Buy regulated legacy software, rebuild it AI-native, sell to an acquirer that can't build AI fast enough. Watch which compliance category - financial, legal, quality - gets the same treatment next.

Two. Simulation companies are buying downstream to feed their models. Dassault doesn't need ArisGlobal's revenue; it needs the 12 million safety reports a year that teach its virtual twin what happens after approval. The signal is bigger than pharma: model-owning incumbents are acquiring operational data sources, not just adjacent products. Watch whether Siemens or PTC move the same way.

Three. The contingent AI earnout is becoming standard, and it hides in plain sight. $200 million of the price rides on AI revenue milestones, disclosed as "additional consideration" - a footnote. That footnote is the thesis: Dassault pays full value for what exists, and for the AI story only if it shows up. Watch how many 2026 deals carry an earnout tied to AI revenue, not headcount.

The bear case is real. Dassault is paying more than 10x revenue for a $175 million business, and has promised this before. It paid $5.8 billion for Medidata in 2019, and that loop is still more roadmap than result. Absorption into NavaX and XDI is harder than it sounds, and Veeva owns the cloud these customers run on.

The bull case is sharper. Dassault bought the one missing layer to close that loop - for a third of the Medidata price, all cash, accretive in Year 1. The earnout means it pays for the AI story only if that story shows up. The $1.8 billion isn't the bet. The bet is that connected data from molecule to outcome becomes what the industry buys - and Dassault owns the only stack that spans it.

What to watch: the $200 million earnout, tied to AI revenue. If it goes unpaid, NavaX missed - and so did the premium.

Here is my interview with Mike Ryan, CEO of Bullet Point Network, who was earlier Partner at Goldman Sachs, Global Co-Head of Equities, investment committee at Harvard's endowment.

If you enjoyed our analysis, we’d very much appreciate you sharing with a friend.

Here are the options I have for us to work together. If any of them are interesting to you - hit me up!

And that’s it from me. See you next week.

What do you think about my bi-weekly Newsletter? Love it | Okay-ish | Stop it